Alzamend Neuro
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alzamend Neuro and other ETFs, options, and stocks.About ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
CEOStephan Jackman
CEOStephan Jackman
Employees7
Employees7
HeadquartersAtlanta, Georgia
HeadquartersAtlanta, Georgia
Founded2016
Founded2016
Employees7
Employees7
ALZN Key Statistics
Market cap2.36M
Market cap2.36M
Price-Earnings ratio-0.11
Price-Earnings ratio-0.11
Dividend yield—
Dividend yield—
Average volume200.79K
Average volume200.79K
High today$2.96
High today$2.96
Low today$2.86
Low today$2.86
Open price$2.87
Open price$2.87
Volume86.20K
Volume86.20K
52 Week high$135.54
52 Week high$135.54
52 Week low$2.75
52 Week low$2.75
People also own
Based on the portfolios of people who own ALZN. This list is generated using Robinhood data, and it’s not a recommendation.